IQWiG Finds Two Conflicting Studies and No Billing Code Behind AI Lung Cancer Reading
In Germany, AI lung reading is a cost radiologists carry and payers never see, and IQWiG wants outcome trials.
The Brief
Latvia Squeezes Access for 123,000 Patients Out of Price Deals as 124 Drugs Wait
Latvia is buying access with manufacturers’ money, inside a reimbursement budget NVD already expects to overrun.
Novartis $7.8 Billion Abogen Bet Rests on Efficacy Data From Three Patients
Up to $7.8 billion for an mRNA engager with efficacy data from three patients, 32 days after Novartis halted its CAR-T.
NICE Backs Tryngolza for FCS, Giving Sobi a Monthly Successor to Its Own Waylivra
Sobi is moving its FCS franchise to a less frequent, better-tolerated drug, on broader NICE terms than the one it replaces.
Pharmac Will Fund Any Medicine for Young People With Paediatric-Origin Cancers, About 15 a Year
The numbers are small, but the rule is unusual: New Zealand funds by tumour type and protocol rather than product by product.
Korea Now Reimburses BeOne’s Tevimbra First-Line in Three Cancers, Using PD-L1 Cutoffs to Set the Limits
One reimbursement decision moved a second-line PD-1 into first line across three common cancers, inside biomarker limits.
Sanofi Pays Regeneron $1 Billion to Keep Dupixent’s Successors Inside a 23-Year Alliance
Sanofi is paying to keep Dupixent’s next generation in the partnership, and the deal also closes a lawsuit between them.
Medicare Advantage Premiums Fall 16.5% for 2027 While Part D Deductibles Rise 30%
The premium headline is real, but part of the cost has moved from the monthly bill to the point of care.
Sweden Subsidised Phesgo in Both Early and Metastatic Breast Cancer as Pertuzumab Biosimilars Approach
A general subsidy in both settings is a clean result for Roche’s subcutaneous strategy, landing before pertuzumab biosimilars.
EU Pharma Package Sets Nine Years’ Default Protection and Rewards Comparative Trials With a Tenth
The default gets shorter, and the route back to the maximum runs through comparative trials and filing early in Europe.